Latest Financial Performance News

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

Tasmea Limited reported a stellar FY25 with strong revenue and profit growth, bolstered by strategic acquisitions and a robust dividend payout. The company signals continued momentum with a new acquisition announcement and targets ASX300 inclusion in 2026.

Schaffer Corporation delivered solid FY25 results with revenue growth and record property valuations, but the Jaguar Land Rover cyberattack clouds the near-term outlook for its Automotive Leather division.

ParagonCare reported solid FY25 results, progressing well on its complex merger integration and expanding its footprint in Asia through the acquisition of Somnotec Group.

Experience Co Limited reported a strong FY25 with record revenue and earnings growth, driven by its Skydiving and Adventure Experiences segments. The company is advancing organic growth and acquisitions while maintaining disciplined capital management heading into FY26.

GTN Limited reported a modest 2% revenue decline and a sharper 26% drop in adjusted EBITDA for FY25, while maintaining strong cash flow and delivering solid shareholder returns.

Clime Investment Management has agreed to sell its retail client book for $1.65 million, marking a strategic shift to focus on its wholesale business and high-net-worth clients.

Nufarm Limited posted a $165.3 million statutory loss for FY25, driven by significant restructuring charges and omega-3 price declines, while announcing a CEO transition effective January 2026.

Whitefield Industrials reported a 4% decline in net profit for the half-year to September 2025 but maintained a strong fully franked dividend and delivered portfolio returns above its benchmark.

LGI Limited reported robust FY25 results with a 14% rise in EBITDA and secured six new contracts, positioning the company for a 25-30% EBITDA increase in FY26. Key project completions and expansions underpin this momentum.

LGI Limited reported robust FY25 results, expanding electricity capacity by 44% and increasing EBITDA by 14%, driven by new landfill gas contracts and battery storage projects. The company is well positioned to capitalize on Australia’s renewable energy transition and evolving carbon credit market.

Cyclopharm Limited reaffirms its ambitious target of 250–300 US Technegas installations by late 2026, driven by FDA approval, CMS reimbursement, and a growing pipeline of healthcare sites. The company reports record half-year revenue growth, signaling strong momentum in the expanding lung imaging market.